protein

Recombinant Human Osteoprotegerin, His Tag

MBS142167

0.01 mg

140 USD

Recombinant Protein

Recombinant Human Osteoprotegerin, His Tag

Osteoprotegerin

OPG Human, His; Osteoprotegerin Human Recombinant, His Tag; TNFRSF11B; OPG; OCIF; Osteoclastogenesis inhibitory factor; TR1; MGC29565; OPG His

tumor necrosis factor receptor superfamily member 11B; Tumor necrosis factor receptor superfamily member 11B; tumor necrosis factor receptor superfamily member 11B; osteoclastogenesis inhibitory factor; osteoprotegerin; tumor necrosis factor receptor superfamily, member 11b; Osteoclastogenesis inhibitory factor; Osteoprotegerin

OPG

TNFRSF11B; TNFRSF11B; OPG; TR1; OCIF; OCIF; OPG

TR11B_HUMAN

E Coli

401

Greater than 80.0% as determined by(a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.

The protein was lyophilized from a concentrated (1mg/ml) solution with 1X PBS, 0.1% SDS and 1mM DTT. Sterile Filtered White lyophilized (freeze-dried) powder.

Lyophilized Osteoprotegerin although stable at room temperature for 3 weeks, should be stored desiccated below -18 degree C. Upon reconstitution OCIF should be stored at 4 degree C between 2-7 days and for future use below -18 degree C.For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.

Western Blot (WB), Antibody Production, Protein assay

1. Positive control for Western blot.2. Antibody production. 3. Protein assay.

Solubility: It is recommended to reconstitute the lyophilized Osteoprotegerin in sterile 18M Omega -cm H2O not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.

CYTOKINES AND GROWTH FACTORS; Growth Factors; Osteoprotegerin

Description: Recombinant Human OCIF produced in E Coli cells is a single, non-glycosylated, polypeptide chain containing amino acids 201-401 and having a molecular mass of 31 kDa which includes a 4 kDa His tag.The OPG is purified by proprietary chromatographic techniques. Introduction: Osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. OPGand its ligand (OPGL) are cytokines regulating osteoclasto-genesis. OPGL binds to receptors on the surface of preosteoclasts and stimulates their differentiation into active osteoclasts. This leads to osteoresorption. OPG inhibits this osteoclasto-genesis (OPG is secreted by osteoblasts, and binds to OPGL, thus inhibiting maturation of osteoclasts and osteoresorption). The degree and activity of osteoresorption depend mainly on the balance between OPG and its ligand (OPGL); factors increasing OPGL expression mostly reduce OPG expression and vice versa.

148743793

NP_002537.3

NM_002546.3

O00300

46,026 Da

Apoptosis Modulation And Signaling Pathway (198822); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Monoamine Transport Pathway (198851); Osteoblast Signaling Pathway (198842); Osteoclast Signaling Pathway (198769); Osteoclast Differentiation Pathway (193147); Osteoclast Differentiation Pathway (193096); RANKL/RANK Signaling Pathway (672447)

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal. Protein type: Inhibitor; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 8q24. Cellular Component: proteinaceous extracellular matrix; extracellular space; extracellular region. Molecular Function: cytokine activity; receptor activity. Biological Process: response to drug; extracellular matrix organization and biogenesis; response to magnesium ion; response to estrogen stimulus; apoptosis; negative regulation of odontogenesis of dentine-containing teeth; response to arsenic; signal transduction; negative regulation of bone resorption; skeletal development; response to nutrient. Disease: Paget Disease, Juvenile

0.01 mg

140 USD

0.05 mg

205

1 mg

2365